Novo Nordisk A/SNVONYSE
Loading
Year-over-year operating cash flow growth rate
| Period | Value |
|---|---|
| Q4 2025 | -83.48% |
| Q3 2025 | 13.05% |
| Q2 2025 | 65.85% |
| Q1 2025 | 99.91% |
| Q4 2024 | -71.95% |
| Q3 2024 | -13.17% |
| Q2 2024 | 252.82% |
| Q1 2024 | 49.87% |
| Q4 2023 | -76.69% |
| Q3 2023 | 43.35% |
| Q2 2023 | -4.15% |
| Q1 2023 | 319.86% |
| Q4 2022 | -70.70% |
| Q3 2022 | 1.16% |
| Q2 2022 | 1.59% |
| Q1 2022 | 881.77% |
| Q4 2021 | -114.03% |
| Q3 2021 | -14.84% |
| Q2 2021 | 124.39% |
| Q1 2021 | 6443.60% |
| Q4 2020 | -99.02% |
| Q3 2020 | -27.84% |
| Q2 2020 | 142.32% |
| Q1 2020 | 93.84% |
| Q4 2019 | -69.05% |
| Q3 2019 | 10.96% |
| Q2 2019 | 52.06% |
| Q1 2019 | 33.43% |
| Q4 2018 | -36.21% |
| Q3 2018 | -26.32% |
| Q2 2018 | 60.67% |
| Q1 2018 | 62.72% |
| Q4 2017 | -53.32% |
| Q3 2017 | 27.72% |
| Q2 2017 | -16.37% |
| Q1 2017 | 8.47% |
| Q4 2016 | -26.57% |
| Q3 2016 | 4.77% |
| Q2 2016 | 93.94% |
| Q1 2016 | -26.13% |